Synonyms: Afinitor® | Certican® | RAD-001 | RAD001 | rapamycin, 42-O-(2-hydroxyethyl)- | Zortress®
everolimus is an approved drug (FDA & EMA (2009))
Compound class:
Synthetic organic
Comment: Everolimus is a Type-3 kinase inhibitor and it was first approved by the FDA in 2009. There is some ambiguity in the literature as to the exact stereochemistry of everolimus. The structure shown here matches that in the Pubchem entry listed in the Database Links table. Other common representations include CID 46930999, CID 70789204 and CID 16211121.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖View more information in the IUPHAR Pharmacology Education Project: everolimus |
|
Immunopharmacology Comments |
Everolimus has immunosuppressant activity that is exploited clinically to prevent rejection of transplanted organs. |